Trials / Not Yet Recruiting
Not Yet RecruitingNCT05784974
Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer
An Open-label, Single-center, Phase II Study of Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- Sponsor
- The First Hospital of Jilin University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of Cadonilimab monotherapy as neoadjuvant therapy for patients with resectable stage II-IIIA squamous cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cadonilimab | 15 mg/kg via intravenous infusion on Day 1 of each 21-day cycle. |
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2025-05-01
- Completion
- 2028-05-01
- First posted
- 2023-03-27
- Last updated
- 2023-03-27
Source: ClinicalTrials.gov record NCT05784974. Inclusion in this directory is not an endorsement.